Melanotan I: uses, evidence and status

compound file

The answer, first. A synthetic alpha-melanocyte-stimulating hormone analogue developed at the University of Arizona in the 1980s and marketed since 2014 as the afamelanotide implant SCENESSE. The strongest evidence is for pain-free light in porphyria, graded A — approval or replicated trials.

Two randomised placebo-controlled implant trials: US median pain-free sunlight 69.4 versus 40.8 hours at six months [P=0.04], EU 6.0 versus 0.8 hours at nine months ¹. Both trials were small: 94 and 74 patients.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Pain-free light in porphyria2 randomised trials, n=168 · supportinggrade ATwo randomised placebo-controlled implant trials: US median pain-free sunlight 69.4 versus 40.8 hours at six months [P=0.04], EU 6.0 versus 0.8 hours at nine months ¹. Both trials were small: 94 and 74 patients.

02Skin darkening without UV2 small trials, n=72 · extensivegrade CIn 65 fair-skinned volunteers melanin density rose 41% in the lowest-baseline group after three 10-day cycles ². A seven-subject study found forearm eumelanin up 98% a week after dosing ³.

03Protection from sunburn1 trial, n=65 · supportinggrade CEpidermal sunburn cells after three minimal erythemal doses fell more than 50% in the low-baseline volunteers, and basal-layer thymine dimers fell 59% [P=0.002] ². Surrogate markers, one trial, 65 people.

04Vitiligo repigmentation1 randomised trial, n=55 · nonegrade CAfamelanotide added to narrowband UV-B beat UV-B alone on the Vitiligo Area Scoring Index in 55 patients ⁴. Single trial, four months, face and upper limbs.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetBinds the melanocortin-1 receptor on melanocytes with far greater potency and duration than the native hormone it copies ³.

2signalReceptor activation raises cyclic AMP and tyrosinase transcription, shifting melanin synthesis toward eumelanin rather than pheomelanin ³.

3effectEumelanin content rises. In seven subjects forearm eumelanin rose 98% a week after dosing stopped ³, and light tolerance improves in porphyria ¹.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

It prevents skin cancer. No trial has measured cancer incidence. Barnetson measured DNA-damage surrogates, thymine dimers down 59%, not tumours ².
A research vial is SCENESSE. Approval attaches to a 16 mg controlled-release implant placed by a trained clinician ⁷. Not to reconstituted powder.
Approved means safe for tanning. The label requires twice-yearly full-body skin examination because the pigmentation darkens existing moles and freckles ⁷.
It replaces sunscreen. No trial has tested it against or alongside sunscreen. The approved indication is a rare photosensitivity disorder, not sun protection ¹⁷.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeSubcutaneous. The approved product is a bioresorbable implant placed above the anterior supra-iliac crest by a trained healthcare professional ⁷.

format16 mg controlled-release implant. Research-market melanotan I is lyophilised powder for reconstitution.

published dosesThe label schedules one 16 mg implant every two months ⁷. The tanning studies used daily subcutaneous injection instead: 0.16 mg/kg for ten days ³, and 0.16 mg/kg across three 10-day cycles over three months ². Those are trial protocols, not label doses.

human pharmacokineticsMedian Tmax 36 hours from the implant, terminal half-life about 15 hours, measurable plasma to 96 hours ⁷.

reported conventionsAs reported on tanning and bodybuilding forums, 2010-2026: a loading phase of small daily injections, then weekly or twice-weekly maintenance. Brief UV exposure is described alongside it. Nasal sprays are also discussed. Convention, not guidance.

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetIn the porphyria trials the primary endpoint was measured at six and nine months ¹. In the 65-person tanning study melanin density rose across three 10-day cycles over three months ². The seven-subject study measured darkening at day 14 and day 21 ³.

most common reportSkin darkening, most pronounced in people with the least baseline pigment ². Nausea early in dosing is the other common report ⁵⁷.

adverse effectsLabel rates, afamelanotide versus vehicle: implant site reaction 21% versus 10%, nausea 19% versus 14%, skin hyperpigmentation 4% versus 0%, melanocytic naevus 4% versus 2% ⁷. Serious hypersensitivity including anaphylaxis is a labelled warning ⁷.

the stop signalThe label sets no stop rule. It requires a full-body skin examination twice yearly and review of any changing lesion ⁷. Case reports of changing moles come from the unregulated melanotan market ⁶.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalFDA approved 8 October 2019 for erythropoietic protoporphyria. EMA approved December 2014.

FDAApproved as SCENESSE, a 16 mg implant placed by trained clinicians. The research-market powder sold as melanotan I is not that product.

sport [WADA]Not named on the Prohibited List. It is an approved medicine.

sold asapproved medicine

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is Melanotan I used for?

Two different things. As afamelanotide it is the approved treatment for increasing pain-free light exposure in adults with erythropoietic protoporphyria. That is a rare disorder in which sunlight causes severe pain.

On the research market the same molecule is bought to darken skin without UV exposure. The approval covers only the first, in a 16 mg implant placed by a trained clinician. It does not extend to a vial or to a cosmetic goal.

How is Melanotan I used?

Two ways, described rather than advised. The approved product is a bioresorbable 16 mg implant placed under the skin above the hip bone every two months by a trained healthcare professional.

The tanning literature used daily subcutaneous injection instead, 0.16 mg/kg, in ten-day cycles. As reported on forums, research-market use follows a loading run of small daily injections, then weekly maintenance, with UV exposure alongside. Convention, not guidance.

How long does Melanotan I take to work?

The trials measured at fixed points rather than tracking onset. In the porphyria trials the primary endpoint sat at six and nine months. In the seven-subject tanning study, darkening was measured on day 14 and again on day 21, a week after the last dose.

In the 65-person study, melanin density was tracked across three ten-day cycles over three months. Nobody has published a time-to-visible-tan curve.

Is Melanotan I an approved drug?

Yes, for one indication. Afamelanotide has been approved in the US since October 2019 and in Europe since 2014, to increase pain-free light exposure in erythropoietic protoporphyria. An approval attaches to a named indication, a named dose and a manufactured product.

It does not extend to a research vial, an off-label goal, or a dose worked out on a forum. Our index grades this molecule approved on clinical evidence and moderate on community adoption, separately and on purpose.

Is Melanotan I safer than Melanotan II?

They are different molecules with different files. Melanotan I is the more selective of the two, and it has been through regulated trials. It carries up to eight years of clinical follow-up across 115 patients in a rare-disease population.

Melanotan II never got past a three-subject pilot and carries the case-report record instead. That is a difference in the evidence, not a safety claim about a gray-market vial of either one.

References

Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373:48-59. PMID 26132941
Barnetson RS, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126:1869-78. PMID 16763547
Dorr RT, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72:526-32. PMID 11045725
Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42-50. PMID 25230094
Biolcati G, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172:1601-1612. PMID 25494545
Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56:975-980. PMID 28266027
SCENESSE [afamelanotide] implant, for subcutaneous use. US prescribing information, DailyMed. dailymed.nlm.nih.gov
Homey B, et al. German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg [SCENESSE] in Patients With Erythropoietic Protoporphyria. Photodermatol Photoimmunol Photomed. 2025;41:e13012. PMID 40082741

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.